The agency last December approved subcutaneous Rybrevant on a biweekly dosing schedule across all of its indications.
The FDA has approved a monthly dosing schedule for subcutaneous amivantamab in NSCLC following the first 4 weeks of treatment ...
INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. today announced the launch of OBODENCE™ (60 mg pre-filled syringe) and XBRYK™ (120 mg vial), denosumab biosimilars referencing Prolia and ...
Wyost is approved for the treatment of cancer-related bone disease and Jubbonti is approved to treat osteoporosis. It builds on other key biosimilar launches this year including Wyost and Jubbonti in ...
Denosumab-kyqq demonstrated similar quality, safety, and efficacy to the reference product. The US Food and Drug Administration (FDA) has approved Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq), ...
Question: My doctor recommended vaccines for this fall, how are they covered by Original Medicare? Answer: Vaccines and injections prescribed by our physicians are covered differently depending on ...
BENGALURU, India and BRIDGEWATER, N.J., Sept. 17, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results